---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-24-000005"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:50:25.936921+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical publishes 483-patient study showing Renuvion safety after liposuction across multiple body areas

## Summary
- Analysis of 483 patients (1,184 body areas) found no new or increased risks vs. liposuction alone.
- Peer-reviewed publication in Aesthetic Surgery Journal Open Forum; data previously used for FDA 510(k) clearance in 2023.
- CEO states evidence strengthens clinical portfolio for Renuvion; no alternative FDA-cleared therapy exists for the indication.

## SEC filing metadata
- accession: 0000719135-24-000005
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913524000005/0000719135-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913524000005/apyx-20240122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-24-000005
- JSON: https://secwatch.observer/filing/0000719135-24-000005.json
- Plain text: https://secwatch.observer/filing/0000719135-24-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.